<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466997</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/05</org_study_id>
    <nct_id>NCT02466997</nct_id>
  </id_info>
  <brief_title>Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC</brief_title>
  <acronym>VITAC</acronym>
  <official_title>Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric French parallel double-blind randomized versus placebo study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric French parallel double-blind randomized versus placebo study, with duration of
      treatment of 6 months, and a post-treatment follow-up period of 6 months
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of repigmented surface area of the target lesion ≥75%</measure>
    <time_frame>One year</time_frame>
    <description>To test the efficacy of a 24 weeks months Tacrolimus 0.1% ointment treatment vs placebo in an adult population with stable non-segmental vitiligo of the face. Therapeutic success is defined as the variation in percentage of repigmented surface area of the target lesion ≥75% at 24 weeks months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in percentage of repigmented surface area</measure>
    <time_frame>24 weeks</time_frame>
    <description>Variation in percentage of repigmented surface area of the target lesion between week 24 and week 48 (observation period) in patients who were successfully treated (observation period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in percentage of repigmented surface area</measure>
    <time_frame>48 weeks</time_frame>
    <description>Variation in percentage of repigmented surface area of the target lesion between week 24 and week 48 (observation period) in patients who were successfully treated (observation period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of patient's global satisfaction using Likert score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Variation of patient's global satisfaction using Likert score at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of patient's global satisfaction using Likert score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Variation of patient's global satisfaction using Likert score at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of patient's global satisfaction using Likert score</measure>
    <time_frame>48 weeks</time_frame>
    <description>Variation of patient's global satisfaction using Likert score at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the physician global evaluation of treatment efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Variation of the physician global evaluation of treatment efficacy on facial vitiligo using Likert score at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the physician global evaluation of treatment efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Variation of the physician global evaluation of treatment efficacy on facial vitiligo using Likert score at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the physician global evaluation of treatment efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Variation of the physician global evaluation of treatment efficacy on facial vitiligo using Likert score at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the Dermatology Life Quality Index</measure>
    <time_frame>24 weeks</time_frame>
    <description>Variation of the Dermatology Life Quality Index (DLQI) between inclusion and after 24 weeks of treatment between the 2 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.
Counselling on natural light exposure during the duration of the trial will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject male or female with age over 18 years old

          2. Diagnosis of non-segmental (symmetrical) vitiligo

          3. Presence of at least one vitiligo target-plaque on the face, with:

             Area greater than 3cm² Local Vitiligo Area Severity Index (VASI) score ≥ 50% Stable
             (no change in pigmentation or size over the last 3 months) Recent onset (less than 2
             years duration)

          4. Subject affiliated to the French social security system

        Exclusion Criteria:

          1. Progressive vitiligo over the last 3 months

          2. Spontaneous ongoing repigmentation (documented in the last 3 months)

          3. Previous topical Tacrolimus treatment in the last 3 months

          4. Previous topical or systemic treatment in the last month:

             Topical or oral corticosteroid Topical vitamin D Phototherapy or laser Other topical
             treatment specific to vitiligo Other immunosuppressant or immunomodulator

          5. Underlying dermatological disease (i.e.: history of atopic dermatitis, eczema,
             psoriasis), which, according to the investigator, could interfere with the study
             assessments

          6. Known sensitivity to study drug or macrolides

          7. Past history of skin cancer or lymphoma

          8. Congenital or acquired immunodeficiency

          9. Pregnant or breastfeeding women

         10. Women without contraception

         11. Absence of signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaled EZZEDINE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khaled EZZEDINE</last_name>
    <phone>33.5.56.79.47.05</phone>
    <email>khaled.ezzedine@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas ANDREU</last_name>
    <phone>33.5.57.82.06.55</phone>
    <email>nicolas.andreu@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Bordeaux - St André Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien SENESCHAL, MD, PhD</last_name>
      <phone>+335.56.79.47.05</phone>
      <email>juline.seneschal@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas ANDREU</last_name>
      <phone>+335 57 82 06 55</phone>
      <email>nicolas.andreu@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Center of Le Mans -</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé MAILLARD, MD</last_name>
      <phone>+332 43 43 43 58</phone>
      <email>hmaillard@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Center of Nice - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PASSERON, MD</last_name>
      <phone>+334 92 03 64 88</phone>
      <email>passeron.t@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Center of Reims - Hôpital Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ziad REGUIAI, MD</last_name>
      <phone>+333 26 78 43 52</phone>
      <email>zreguiai.chu-reims@medical51.apicrypt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Center of Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine DROITCOURT</last_name>
      <phone>+332 99 28 43 49</phone>
      <email>catherine.droitcourt@chu-rennes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Face</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

